Monoclonal Antibodies Market

Global Monoclonal Antibodies Market Size (2024 to 2032)

In 2023, the global monoclonal antibodies market was valued at USD 41.17 Billion and it is expected to reach USD 65.23 Billion by 2032 from USD 43.35 Billion in 2024, growing at a CAGR of 5.3 % during the forecast period.

Current Scenario of the Monoclonal Antibodies Market

The molecules that are produced to fight against the cancer-type cells in the laboratories are simply termed the substitute’s antibodies. These antibodies have the potential to fight against unwantedly growing cells like Cancer. They can improve the overall immune system and enhance the overall health of a person. The rising number of people suffering from various types of cancer diseases is accumulated in leveraging the demand for monoclonal antibodies. According to the Centre for Disease Control and Prevention (CDC), Cancer is becoming a huge concern across the world as it is one of the leading diseases causing high fatalities every year. For instance, in the US, approximately 1.9 million people were diagnosed with Cancer, and. The number of deaths due to Cancer was 609,360 in 2023. These statistics showcase the huge importance of developing vigorous research activities to launch innovative drugs that combat the risk of cancer diseases. According to WHO (World Health Organization), 50% of cancer deaths can be prevented by early diagnosis and the management of diseases with the available drugs or treatment procedures. Therefore, there is a huge scope for the monoclonal antibodies market growth in the coming years.

MARKET DRIVERS

The growing global chronic disease patient population primarily drives the worldwide monoclonal antibodies market growth.

The invention of new monoclonal antibody applications significantly influences this market's growth rate. Furthermore, the rise in healthcare infrastructure investment will likely boost the global mABs market. The development of new molecules is expected to play a prominent role in the market's future due to this technology's cost-effectiveness.

The demand to ensure quality healthcare services is accelerating the growth rate of the monoclonal antibodies market.

The advancement of genomics research and development activities and the emergence of technologically advanced genetic platforms, such as next-generation sequencing, have contributed significantly to the market and helped the existing companies in the global mABs market grow further. The emergence of advanced technology, the launch of innovative products in the biotechnology field, and economic growth in developed and developing countries are surging the demand for the monoclonal antibodies market. Growing knowledge of genomics, the trend toward next-generation sequencing, and ease in the availability of various resources used in the research centers fuel the market's growth rate. Rising awareness of therapies and other biological parameters impacts the market's growth.

MARKET RESTRAINTS

The treatment for chronic diseases is generally cloned with various side effects, and many people come across different health-related problems like fatigue, weakness, and others, which is certainly a major factor hindering the growth rate of the monoclonal antibodies market. Generally, producing monoclonal antibodies is a complex and difficult procedure due to which the speed and scale of completion of these therapeutic procedures is long-term. These slow progress in performing high level procedures in less time can be a great challenging factor in the healthcare which is to decline the growth rate of the market. Higher investments in research and development activities can also impede the growth rate of the market in the future. Though the monoclonal antibodies therapeutic procedures are highly accurate and trending procedures to treat various chronic diseases, including inflammatory diseases and Cancer, the problem arises in investing huge amounts initially for research purposes. Also, the cost of these treatment procedures is relatively very high, and common people cannot afford them, which is likely to limit the fastest growth rate of the market during the forecast period. The rising economic crisis in many countries can negatively affect the growth rate of the market in the future.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Monoclonal Antibodies Market Analysis By Source

The murine segment held the largest share of the global monoclonal antibodies market in 2023 and the segmental domination is anticipated to continue throughout the forecast period due to the development of modern antibody production techniques and immunoglobulins for therapeutic and analytical applications. On the other hand, the chimeric segment is expected to have the highest growth rate in the coming years. An increasing number of people suffering from various health disorders is a specific factor for this segment to grow.

On the other hand, the humanized monoclonal segment is one of the most lucrative segments and is expected to grow at a healthy rate during the forecast period. The extensive adoption of innovative techniques for treating various diseases, such as Cancer and inflammatory disorders, propels this segment's demand. In addition, progressive genetic engineering technology engaged in its production is one of the significant factors driving the segmental expansion.

Global Monoclonal Antibodies Market Analysis By Indication

Based on the indication, the cancer disease segment is ruling the market currently and will account for a dominating share of the mABs market in 2023. Adopting sedentary lifestyles and changing food habits are some attributes for the cancer segment to grow. Therefore, this segment will continue its dominance throughout the forecast period. The segment growth is further majorly driven by the high increase in the incidence of cancer and healthcare reimbursement policies. In addition, intensifying the drug pipeline integrated with treatment approvals and clinical trials is projected to generate profitable growth opportunities in the monoclonal antibodies market.

Global Monoclonal Antibodies Market Analysis By End-user

The hospitals /clinics segment is forecasted to register the most significant share of the monoclonal antibodies market and is central to the increasing healthcare centers and clinics scale. Besides, the growing geriatric population is enhancing the market's growth rate. In addition, the rising patient population and a growing number of chronic disease patients are increasing the demand for this segment. Furthermore, this segment is also expected to be favored by increasing chronic ailments, growing healthcare expenses, and raising awareness among the patient population about alternative treatments.

Global Monoclonal Antibodies Market Analysis By Application

Based on the application, the medical segment led the monoclonal antibodies market worldwide in 2023, owing to a rise in research and development activities. Monoclonal antibodies are replicas of the human body's antibodies made in a laboratory and used to boost the immune system. These are used in medicals in such a way that monoclonal antibodies as therapies and for other treatments of cancers. These are used as immunotherapy because these immune systems fight against Cancer. In addition, different types of vaccines are available based on monoclonal antibodies.

The ELISA segment fosters the monoclonal antibody market during the forecast period. ELISA methods are used on monoclonal antibodies, which is driving the segmental growth. This method detects and quantifies a specific protein in a complex mixture.

REGIONAL ANALYSIS

Geographically, the North American monoclonal Antibodies Market dominates the global market due to the well-established healthcare infrastructure in this Region, the increased importance given to state infection control and management, and the growing prevalence of lifestyle-related health issues. Furthermore, the market will continue to grow during the forecast period, owing to amplified public investments in cancer research and technological development. Therapeutic monoclonal antibodies have been increasing yearly, and it is estimated that 106 monoclonal antibodies have been approved in the United States. In Canada, monoclonal antibodies are used more widely due to the increase in cases of Covid-19 infection. Researchers in Canada have manufactured different monoclonal antibodies to treat many diseases, such as severe asthma, rheumatoid arthritis, multiple sclerosis, infectious diseases, and Cancer.

The European market is predicted to grow at a notable compound annual growth rate (CAGR %) during the forecast period. The European Commission has advised the European Medicines Agency (EMA) to follow the guidelines that medicine should contain monoclonal antibodies against the spike protein of the SARS-CoV-2 virus. Europe has been in an advanced state to approve different types of monoclonal antibodies for different diseases. In Germany, Sotrovimab is another COVID-19 treatment option available in this Region to reduce infection rates. The European Commission also approved Xevudy in 2023 to treat COVID-19 in adults over 12 years.

The Asia-Pacific Monoclonal Antibodies Market is also anticipated to increase significantly due to improved lifestyles and increasing awareness about mAbs among patients, advanced research, and development costs. However, due to the lack of penetration, the Asia Pacific market has a high potential to grow during the forecast period. 

The Latin American region is estimated to control a considerable share of the global market during the forecast period.

The MEA market is witnessed to reach a CAGR of 12.95% during the forecast period. In Middle East Africa, coronavirus has infected many people with high mortality. Therefore, this Region provides highly effective therapeutics and vaccines against the coronavirus to save human lives.

KEY PLAYERS IN THE GLOBAL MONOCLONAL ANTIBODIES MARKET

Companies leading the global monoclonal antibodies market profiled in the report are GlaxoSmithKline PLC, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly, And Shanghai Junshi Bioscience Co., Ltd.Company, Seattle Genetics, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Lt.

RECENT HAPPENINGS IN THE MARKET

• In 2023, Roche acquired the rights to Novel TL1ADirected Antibody (RVT-3101) of Televant. Both companies entered into a definitive agreement to develop or manufacture RVT-3101 in the US and Japan, which is to treat inflammatory bowel diseases effectively. Currently, RVT-3101 is a Phase III-ready antibody with the best potential results in Phase II data in ulcerative colitis. Roche is also planning to enter into a global collaboration with Pfizer to develop next-generation p40/TL1A, which is currently in Phase I.
• In 2024,  Abbvie Incand OSE Immunotherapeutics jointly to develop OSE 320, a monoclonal antibody that can be used to treat chronic and severe inflammation.  Abbvie Inc is all set to receive an exclusive global license to develop, manufacture, and commercialize OSE 320 where OSE immunotherpeutics is receiving whopping investments for developing the same from various sources. Therefore, these two companies partnered together to promote the antibody globally.

DETAILED SEGMENTATION OF THE GLOBAL MONOCLONAL ANTIBODIES MARKET INCLUDED IN THIS REPORT

This research report on the global monoclonal antibodies market has been segmented and sub-segmented based on the source, indication, end-user, application, and region.

By Source

• Murine
• Chimeric
• Humanized
• Human

By Indication

• Cancer
  • Blood Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Pancreatic Cancer
  • Others
• Autoimmune Diseases
• Infectious Diseases
• Cardiovascular Diseases
• CNS Disorders
• Others (Inflammatory, Microbial Diseases, & Others)

By End-User

• Hospitals/Clinics
• Research Institute
• Diagnostic Laboratories

By Application

• Medical
• Experimental
• Western Blot
• ELISA
• Radioimmune Assays
• Immunofluorescence
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa